SUCLG2 and prostate carcinoma: In prostate cancer cells, SUCLG2 enhances the succinic synthetase activity of mitochondrial nucleoside diphosphokinase and promotes leukemia suppressor receptor signaling to enhance prostate cancer aggressiveness [17].